Concordia Healthcare Corp., an integrated and specialty healthcare company, has filed a submission with Health Canada for approval to market Ulesfia in Canada.
Ulesfia (benzyl alcohol) lotion is a prescription non-pesticide head lice treatment currently sold in the United States.
"The filing of Ulesfia with Health Canada begins the expansion of our products into other geographic regions," said Mark Thompson, chief executive officer of Concordia. "The filing begins the 180 day review process and during that time we will look for a partner to promote Ulesfia in Canada."
Concordia Healthcare is focused on legacy pharmaceutical products, orphan drugs and medical devices for the diabetic population.